Bakterien transformiert mit Expressionsplasmiden, die für den menschlichen NEUROTHROPHEN WIMPER FAKTOR (h-CNTF) kodieren, ihre Verwendung in der Herstellung von h-CNTF, Antikörper gegen h-CNTF und die Anwendung von h-CNTF in medizischer Behandlung

The present invention relates to nucleic acid sequences encoding ciliary neurotrophic factor (CNTF) and to the proteins, peptides, and derivatives produced therefrom. In various embodiments of the invention, the nucleic acid sequences, proteins, and peptides of the invention may be used in the treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SENDTNER, MICHAEL, D-8000 MUENCHEN 21, DE, GOTZ, RUDOLF, GEORG, D-8000 MUENCHEN 60, DE, LINDHOLM, DAN, B., D-8000 MUENCHEN 60, DE, IP, NANCY, STAMFORD, CT 06902, US, MASIAKOWSKI, PIOTR, TARRYTOWN, NY 01591, US, KREUTZBERG, GEORG, W., D-8000 MUENCHEN 60, DE, THOENEN, HANS, FRIEDRICH, ERWIN, D-8000 MUENCHEN 40, DE, PANAYOTATOS, NIKOS, ORANGEBURG, NY 10962, US, CARROLL, PATRICK, DESMOND, D-8000 MUENCHEN 2, DE, FURTH, MARK, E., PELHAM, NY 10803, US, STOCKLI-RIPPSTEIN, KURT, A., D-8000 MUENCHEN 70, DE, ARAKAWA, YOSHIHIRO, D-8000 MUENCHEN 71, DE, LOTTSPEICH, FRIEDRICH, D-8021 NEURIED, DE, WONG, VIVIEN, ARDSLEY, NY 10502, US
Format: Patent
Sprache:ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to nucleic acid sequences encoding ciliary neurotrophic factor (CNTF) and to the proteins, peptides, and derivatives produced therefrom. In various embodiments of the invention, the nucleic acid sequences, proteins, and peptides of the invention may be used in the treatment of a variety of neurological diseases and disorders, including Alzheimer's disease. In a specific embodiment of the invention, CNTF may be used to support the growth of spinal cord neurons, thereby providing a method of treating spinal cord damage caused by trauma infarction, infection, nutritional deficiency or toxic agents.The present invention also relates to a novel method for producing substantilly pure CNTF.The invention also relates to pharmaceutical compositions comprising effective amounts of CNTF gene products which may be used in the diagnosis and treatment of a variety of neurologial diseases and disorders.The present invention relates to the cloning sequencing and expression of CNTF and provides, for the first time, a means for producing human CNTF utilizing human CNTF-encoding nucleic acid sequences. Furthermore, the CNTF nucleic acid sequences of the invention may be utilized to identify nucleic acid sequences encoding CNTF or CNTF-homologous molecules in a variety of species and tissues.